Stay updated with breaking news from James Dentzer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LEXINGTON, Mass., April 4, 2024 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James...
(RTTNews) - Curis, Inc. (CRIS), Tuesday said it has reached a clinical trial agreement with the University of Florida to study the combination of ...
LEXINGTON, Mass., Sept. 6, 2023 /PRNewswire/ -- Curis, Inc. , a biotechnology company focused on the development of emavusertib, an orally available small molecule IRAK4 inhibitor for the treatment...
Removal of partial clinical hold – enrolling patients at confirmed RP2D in the TakeAim Leukemia Study Enrolling patients in the TakeAim Lymphoma Study in combination with ibrutinib Strong balance...
A partial clinical trial hold has been lifted from cancer drug emavusertib and Curis has selected a dose to use in Phase 2 testing. The small molecule is being developed as a potential treatment for blood cancers.